Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 1,694 trials

Colitis from Cancer Treatment: The iCaD Study

We are comparing a new treatment combining infliximab with corticosteroids for severe colitis caused by immune checkpoint inhibitors. This study aims to see if this combination is more effective than corticosteroids alone.

Immune Checkpoint Inhibitor Related Colitis≤3 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Crohn's Disease: Multi-Donor Fecal Microbiota Transfer Study

We are investigating whether multi-donor fecal microbiota transfer can help maintain remission in children and adults with Crohn's disease after dietary treatment. The study will assess safety, feasibility, and quality of life for participants.

Crohn's Disease6-12 monthsSafety phase (I)Efficacy phase (II)Investigational MedicinesGastroenterologyPediatrics

Castration-Resistant Prostate Cancer: Lutetium [177Lu] VIPIVOTIDE TETRAXETAN

We are studying a new treatment for men with castration-resistant prostate cancer to see how well it works alone and with other medications. The goal is to evaluate its effects on prostate-specific antigen (PSA) levels and overall health.

Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteOncology

Gastrointestinal Stromal Tumor: Ripretinib vs Sunitinib

We are comparing two treatments for advanced gastrointestinal stromal tumors in patients with specific genetic mutations who have been treated before. The goal is to find out which medication may help control the disease better and improve quality of life.

Advanced Gastrointestinal Stromal TumorConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ODM-212 Study

We are testing a new oral medication, ODM-212, in patients with advanced solid tumors to evaluate its safety and how well it may work. This study aims to find the best dose and understand its effects on tumor growth.

Neoplasms (Tumors)>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: HUVR-CARTemis-1 T-Cell Therapy

We are studying a new T-cell therapy for patients with multiple myeloma who have relapsed after an allogeneic transplant. The trial aims to evaluate the safety and effectiveness of this treatment over time.

Multiple Myeloma Progression>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

Cystic Fibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Kidney Cancer: Savolitinib Plus Durvalumab Study

We are exploring whether a new combination treatment can help patients with advanced papillary renal cell carcinoma live longer and feel better compared to standard therapies.

Clear Cell Papillary Renal Cell CarcinomaConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Limb Girdle Muscular Dystrophy 2E/R4: SRP-9003 Gene Therapy

We are studying a new gene therapy to see if it improves muscle function in people with Limb Girdle Muscular Dystrophy 2E/R4. The trial will evaluate its safety and effectiveness over time.

Limb-girdle Muscular Dystrophy Type 2E/R4>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinology

Asymptomatic Heart Failure: TREASURE Trial

We are studying whether an ACE inhibitor can improve heart health in women with asymptomatic heart failure compared to usual care. The trial also looks at its effects on heart function, metabolic health, and quality of life.

Subclinical Heart Failure>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Advanced Melanoma: Lifileucel with Pembrolizumab

We are investigating whether a new treatment combining lifileucel with pembrolizumab is more effective than pembrolizumab alone for patients with untreated, advanced melanoma. The study aims to assess both effectiveness and safety.

MelanomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

ANCA-Associated Vasculitis: Avacopan Study

We are testing the long-term safety and effectiveness of Avacopan for people with ANCA-associated vasculitis. The study will also look at how it affects remission and overall quality of life.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineRheumatology

Recurrent Miscarriages: PREMI Trial on Prednisolone

We are studying whether prednisolone can help women with unexplained recurrent miscarriages achieve a live birth. The trial compares this treatment to a placebo and looks at pregnancy outcomes and safety.

Recurrent Miscarriages1-2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology